- Home
- BARK vs AVIR Comparison
BARK vs AVIR Comparison
Compare BARK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BARK | AVIR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 429.1M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BARK | AVIR |
|---|---|---|
| Price | $8.98 | $5.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $37.50 | $10.00 |
| AVG Volume (30 Days) | 44.2K | ★ 216.2K |
| Earning Date | 06-03-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $394,843,000.00 | $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | $111.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $2.78 |
| 52 Week High | $11.32 | $6.45 |
Technical Indicators
Market Signals| Indicator | BARK | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 48.26 |
| Support Level | $8.38 | $5.03 |
| Resistance Level | $9.98 | $5.79 |
| Average True Range (ATR) | 0.55 | 0.19 |
| MACD | -0.18 | -0.06 |
| Stochastic Oscillator | 17.86 | 25.00 |
Price Performance
Historical ComparisonAbout BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.